Hodgkin lymphoma outcomes in the novel agent era, genomic safe harbors for precision T cell engineering, and a transcriptomic atlas to map imatinib resistance in CML
Blood Podcast
00:00
A Single Cell Atlas Identifies Predicted Sites for Targeted Transgene Integration
The GSH-6 CAR-T cells resisted multiple tumor re-challenges, including one re-challenge 100 days after infusion. These results suggest a profile that may help avoid tonic elevated car signaling and premature exhaustion of theCAR-T cells. In contrast to the track CAR-T cell, the GSH-4 CAR-T Cells retain a normal T-cell receptor, which may help increase in vivo expansion in some cases.
Transcript
Play full episode
